(MNPR) –
-
Form 10-K Monopar Therapeutics For: Dec 31
-
Form 8-K Monopar Therapeutics For: Mar 28
-
Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments
-
Form 8-K Monopar Therapeutics For: Mar 07
-
Form 8-K Monopar Therapeutics For: Mar 05
-
Monopar Therapeutics (MNPR) Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program
-
Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program
-
Form 8-K Monopar Therapeutics For: Feb 27
-
Form 8-K Monopar Therapeutics For: Feb 27
-
Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
-
Monopar Therapeutics (MNPR) Reports Preclinical Data for MNPR-101
-
Form 8-K Monopar Therapeutics For: Feb 22
-
Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers
-
Monopar Therapeutics (MNPR) Cleared to Proceed with First-in-Human Phase 1 Trial of MNPR-101-Zr
-
Form 8-K Monopar Therapeutics For: Feb 20
-
Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers
-
Form 4 Monopar Therapeutics For: Dec 31 Filed by: Brown Michael J
-
Form 4 Monopar Therapeutics For: Dec 31 Filed by: Anderson Raymond
-
Form 4 Monopar Therapeutics For: Dec 31 Filed by: KLAUSNER ARTHUR J
-
Form 4 Monopar Therapeutics For: Dec 31 Filed by: Cittadine Andrew
-
Form 4 Monopar Therapeutics For: Dec 31 Filed by: STARR CHRISTOPHER M
-
Form 4 Monopar Therapeutics For: Dec 31 Filed by: Robinson Chandler
-
Form 4 Monopar Therapeutics For: Dec 31 Filed by: Tsuchimoto Kim R
-
Form 4 Monopar Therapeutics For: Jan 01 Filed by: RIOUX PATRICE
-
Form 10-Q Monopar Therapeutics For: Sep 30
-
Form 8-K Monopar Therapeutics For: Nov 09
-
Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments
-
Monopar Therapeutics (MNPR) Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b
-
Form 8-K Monopar Therapeutics For: Nov 01
-
Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
-
Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference
-
Form 4 Monopar Therapeutics For: Sep 30 Filed by: Robinson Chandler
-
Form 4 Monopar Therapeutics For: Sep 30 Filed by: Tsuchimoto Kim R
-
Form 4 Monopar Therapeutics For: Sep 30 Filed by: STARR CHRISTOPHER M
-
Form 4 Monopar Therapeutics For: Sep 30 Filed by: KLAUSNER ARTHUR J
-
Form 4 Monopar Therapeutics For: Sep 30 Filed by: Brown Michael J
-
Form 4 Monopar Therapeutics For: Sep 30 Filed by: Anderson Raymond
-
Form 4 Monopar Therapeutics For: Sep 30 Filed by: Cittadine Andrew
-
Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
-
Form 8-K Monopar Therapeutics For: Aug 28
-
Jones Trading Downgrades Monopar Therapeutics (MNPR) to Hold
-
Form 10-Q Monopar Therapeutics For: Jun 30
-
Form 8-K Monopar Therapeutics For: Aug 10
-
Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments
-
Form 8-K Monopar Therapeutics For: Aug 08
-
Monopar Provides Encouraging Camsirubicin Clinical Data Update
-
Monopar Therapeutics (MNPR) Announces MNPR-101 Radiopharma Collaboration Agreement with CSI Singapore
-
Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore
-
Form 8-K Monopar Therapeutics For: Jul 11
-
Form 4 Monopar Therapeutics For: Jun 30 Filed by: Cittadine Andrew
Back to MNPR Stock Lookup